Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum

BackgroundIn view of the need to continuously feed the pipeline with new anti-malarial agents adapted to differentiated and more stringent target product profiles (e.g., new modes of action, transmission-blocking activity or long-duration chemo-protection), a chemical library consisting of more than 250,000 compounds has been evaluated in a blood-stage Plasmodium falciparum growth inhibition assay and further assessed for chemical diversity and novelty.MethodsThe selection cascade used for the triaging of hits from the chemical library started with a robust three-step in vitro assay followed by an in silico analysis of the resulting confirmed hits. Upon reaching the predefined requirements for selectivity and potency, the set of hits was subjected to computational analysis to assess chemical properties and diversity. Furthermore, known marketed anti-malarial drugs were co-clustered acting as ‘signposts’ in the chemical space defined by the hits. Then, in cerebro evaluation of the chemical structures was performed to identify scaffolds that currently are or have been the focus of anti-malarial medicinal chemistry programmes. Next, prioritization according to relaxed physicochemical parameters took place, along with the search for structural analogues. Ultimately, synthesis of novel chemotypes with desired properties was performed and the resulting compounds were subsequently retested in a P. falciparum growth inhibition assay.ResultsThis screening campaign led to a 1.25% primary hit rate, which decreased to 0.77% upon confirmatory repeat screening. With the predefined potency (EC50 < 1 μM) and selectivity (SI > 10) criteria, 178 compounds progressed to the next steps where chemical diversity, physicochemical properties and novelty assessment were taken into account. This resulted in the selection of 15 distinct chemical series.ConclusionA selection cascade was applied to prioritize hits resulting from the screening of a medium-sized chemical library against blood-stage P. falciparum. Emphasis was placed on chemical novelty whereby computational clustering, data mining of known anti-malarial chemotypes and the application of relaxed physicochemical filters, were key to the process. This led to the selection of 15 chemical series from which ten confirmed their activity when newly synthesized sample were tested.

[1]  M. Barrett,et al.  Emerging paradigms in anti-infective drug design , 2014, Parasitology.

[2]  D. Leroy,et al.  Antimalarial drug discovery – the path towards eradication , 2013, Parasitology.

[3]  M. Gilson,et al.  Public domain databases for medicinal chemistry. , 2012, Journal of medicinal chemistry.

[4]  Yingyao Zhou,et al.  Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. , 2008, Nature chemical biology.

[5]  Trixie Wagner,et al.  Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria , 2010, Journal of medicinal chemistry.

[6]  Peter G. Schultz,et al.  In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.

[7]  D. Leroy,et al.  Challenges in antimalarial drug discovery. , 2011, Future medicinal chemistry.

[8]  J. Bourguignon,et al.  Regiospecific Functionalization of Indole-2-carboxylates and Diastereoselective Preparation of the Corresponding Indolines , 1999 .

[9]  M. Hann Molecular obesity, potency and other addictions in drug discovery , 2011 .

[10]  J. Bourguignon,et al.  Regiospecific Functionalization of Indole‐2‐carboxylates and Diastereoselective Preparation of the Corresponding Indolines. , 2000 .

[11]  Richard J Maude,et al.  The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia , 2009, Malaria Journal.

[12]  C. Abad-Zapatero,et al.  Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.

[13]  Jeremy N. Burrows,et al.  The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases , 2013, PloS one.

[14]  Dimitris K. Agrafiotis,et al.  Library Enhancement through the Wisdom of Crowds , 2011, J. Chem. Inf. Model..

[15]  Brett A Tounge,et al.  Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.

[16]  J. Cook,et al.  Mechanistic studies on the cis to trans epimerization of trisubstituted 1,2,3,4-tetrahydro-beta-carbolines. , 2010, The Journal of organic chemistry.

[17]  Matthew E Welsch,et al.  Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.

[18]  I. Jolliffe Principal Component Analysis , 2002 .

[19]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[20]  R. Cibulskis,et al.  World Malaria Report 2013 , 2014 .

[21]  John P. Overington,et al.  Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.

[22]  Phenotypic Screens, Chemical Genomics, and Antimalarial Lead Discovery , 2011, PLoS pathogens.

[23]  Bruce Russell,et al.  Spiroindolones, a Potent Compound Class for the Treatment of Malaria , 2010, Science.

[24]  David M. Shackleford,et al.  Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. , 2011, Journal of medicinal chemistry.

[25]  Yingyao Zhou,et al.  Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery , 2011, Science.

[26]  D. Fidock,et al.  How can we identify parasite genes that underlie antimalarial drug resistance? , 2011, Pharmacogenomics.

[27]  Francisco-Javier Gamo,et al.  Global phenotypic screening for antimalarials. , 2012, Chemistry & biology.

[28]  P. Rathod,et al.  Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. , 2008, Journal of medicinal chemistry.

[29]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[30]  V. Avery,et al.  Development and Optimization of a Novel 384-Well Anti-Malarial Imaging Assay Validated for High-Throughput Screening , 2012, The American journal of tropical medicine and hygiene.